Healwell AI Inc.

TSX:AIDX Stock Report

Market Cap: CA$269.4m

Healwell AI Valuation

Is AIDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AIDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AIDX (CA$1.68) is trading above our estimate of fair value (CA$1.29)

Significantly Below Fair Value: AIDX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AIDX?

Key metric: As AIDX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AIDX. This is calculated by dividing AIDX's market cap by their current revenue.
What is AIDX's PS Ratio?
PS Ratio11.4x
SalesCA$24.57m
Market CapCA$269.45m

Price to Sales Ratio vs Peers

How does AIDX's PS Ratio compare to its peers?

The above table shows the PS ratio for AIDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
CARE Dialogue Health Technologies
3.6x18.8%CA$346.0m
VMD Viemed Healthcare
1.8x17.8%CA$311.8m
QIPT Quipt Home Medical
0.5x5.6%CA$167.2m
AND Andlauer Healthcare Group
2.6x4.6%CA$1.7b
AIDX Healwell AI
11.4x50.1%CA$269.4m

Price-To-Sales vs Peers: AIDX is expensive based on its Price-To-Sales Ratio (11.4x) compared to the peer average (1.6x).

Price to Sales Ratio vs Industry

How does AIDX's PS Ratio compare vs other companies in the CA Healthcare Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
DOC CloudMD Software & Services
0.1xn/aUS$7.82m
NPTH NeuPath Health
0.1xn/aUS$6.42m
PHA Premier Health of America
0.05x4.3%US$5.33m
BLMH Bloom Health Partners
0.1xn/aUS$2.85m
AIDX 11.4xIndustry Avg. 1.1xNo. of Companies8PS00.61.21.82.43+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AIDX is expensive based on its Price-To-Sales Ratio (11.4x) compared to the North American Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is AIDX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AIDX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.4x
Fair PS Ratio7.8x

Price-To-Sales vs Fair Ratio: AIDX is expensive based on its Price-To-Sales Ratio (11.4x) compared to the estimated Fair Price-To-Sales Ratio (7.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AIDX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$1.68
CA$3.81
+126.9%
14.7%CA$5.00CA$3.00n/a8
Nov ’25CA$1.34
CA$3.66
+173.3%
18.7%CA$5.00CA$2.50n/a8
Oct ’25CA$1.50
CA$3.91
+160.7%
16.4%CA$5.00CA$3.00n/a5
Sep ’25CA$1.84
CA$3.91
+112.5%
16.4%CA$5.00CA$3.00n/a5
Aug ’25CA$2.13
CA$3.91
+83.6%
16.4%CA$5.00CA$3.00n/a5
Jul ’25CA$2.53
CA$3.91
+54.5%
16.4%CA$5.00CA$3.00n/a5
Jun ’25CA$1.88
CA$2.24
+19.0%
8.7%CA$2.50CA$1.95n/a4
May ’25CA$1.50
CA$1.34
-10.8%
12.8%CA$1.50CA$1.10n/a4
Apr ’25CA$0.93
CA$1.28
+38.0%
12.9%CA$1.50CA$1.10n/a3
Mar ’25CA$1.11
CA$1.28
+15.6%
12.9%CA$1.50CA$1.10n/a3
Feb ’25CA$0.69
CA$1.30
+88.4%
15.4%CA$1.50CA$1.10n/a2
Jan ’25CA$0.75
CA$1.30
+73.3%
15.4%CA$1.50CA$1.10n/a2
Dec ’24CA$0.98
CA$1.30
+32.7%
15.4%CA$1.50CA$1.10n/a2
Mar ’24CA$0.58
CA$1.20
+106.9%
16.7%CA$1.40CA$1.00CA$1.112
Feb ’24CA$0.70
CA$1.20
+71.4%
16.7%CA$1.40CA$1.00CA$0.692
Jan ’24CA$0.60
CA$1.20
+100.0%
16.7%CA$1.40CA$1.00CA$0.752
Dec ’23CA$0.54
CA$1.20
+122.2%
16.7%CA$1.40CA$1.00CA$0.982
Nov ’23CA$1.00
CA$1.80
+80.0%
16.7%CA$2.10CA$1.50CA$0.672

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

dentalcorp Holdings

CA$1.9b

Through its subsidiaries, engages in the acquiring and partnering with dental practices to provide health care services in Canada.

DNTL

CA$10.16

7D

2.8%

1Y

73.4%

NeuPath Health

CA$9.3m

Provides chronic pain management services in Canada.

NPTH

CA$0.16

7D

-3.0%

1Y

0%

WELL Health Technologies

CA$1.3b

Operates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.

WELL

CA$5.02

7D

1.8%

1Y

35.3%